hyperuricemia
Conditions
Interventions
1.febuxostat40mg 2.febuxostat20mg+benzbromarone25mg 3.benzbromarone50mg
1.benzbromarone50mg 2.febuxostat20mg+benzbromarone25mg 3.febuxostat40mg
Sponsors
National Cerebral and Cardiovascular Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: hypertensive patients with hyperuricemia, whose serum uric acid level >8 mg/dL on untreated or serum uric acid level >6 mg/dL in spite of taking UA lowering drugs over three months.
Exclusion criteria
Exclusion criteria: resistant hypertensive patient (SBP>=180mmHg or DBP>=110mmHg), heart failure patient (more than NYHA classification III or EF<=35%), severe renal damage patient (serum creatinine level >2 mg/dL), impaired liver function patient (AST or ALT>=100IU/ml), the patient with myocardial infarction, angina, and stroke within six months, an acute gouty attack patient, the patient with renal stone, the patient with taking mercaptopurine hydrate, azathioprine or warfarin, the patient with hypersensitivity to benzbromarone or febuxostat, patients to whom the doctor judged the participation in an examination to be unsuitable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum uric acid, uric acid clearance, adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| blood pressure. renal function, oxidant stress, endothelial function, renal artery resistance, inflammation | — |
Countries
Japan
Outcome results
None listed